S-adenosyl-l-methionine (SAMe) as an antidepressant:
meta-analysis of clinical studies
by
Bressa GM
Department of Psychiatry,
University Cattolica Sacro Cuore
School of Medicine, Rome, Italy.
Acta Neurol Scand Suppl 1994; 154:7-14

ABSTRACT

INTRODUCTION--S-adenosyl-l-methionine (SAMe) is a naturally-occurring substance which is a major source of methyl groups in the brain. MATERIAL AND METHODS--We conducted a meta-analysis of the studies on SAMe to assess the efficacy of this compound in the treatment of depression compared with placebo and standard tricyclic antidepressants. RESULTS--Our meta-analysis showed a greater response rate with SAMe when compared with placebo, with a global effect size ranging from 17% to 38% depending on the definition of response, and an antidepressant effect comparable with that of standard tricyclic antidepressants. CONCLUSION--The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants. Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.

SAMe
Options
Cannabis
Hypericum
SAMe mania
Natural drugs
SAMe: efficacy
SAMe: mechanisms
SAMe as an antidepressant
SAMe for depressed HIV/AIDs victims
SAMe (SAMe): bioavailability and safety
SAMe (S-adenosyl-L-methionine) versus imipramine (Tofranil)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family